| Literature DB >> 35631580 |
Olga Yu Griaznova1,2,3, Iaroslav B Belyaev1,3, Anna S Sogomonyan1,3, Ivan V Zelepukin1,3, Gleb V Tikhonowski3, Anton A Popov3, Aleksei S Komlev4, Petr I Nikitin3,5, Dmitry A Gorin2, Andrei V Kabashin3,6, Sergey M Deyev1,3.
Abstract
Hybrid multimodal nanoparticles, applicable simultaneously to the noninvasive imaging and therapeutic treatment, are highly demanded for clinical use. Here, Fe-Au core-satellite nanoparticles prepared by the method of pulsed laser ablation in liquids were evaluated as dual magnetic resonance imaging (MRI) and computed tomography (CT) contrast agents and as sensitizers for laser-induced hyperthermia of cancer cells. The biocompatibility of Fe-Au nanoparticles was improved by coating with polyacrylic acid, which provided excellent colloidal stability of nanoparticles with highly negative ζ-potential in water (-38 ± 7 mV) and retained hydrodynamic size (88 ± 20 nm) in a physiological environment. The ferromagnetic iron cores offered great contrast in MRI images with r2 = 11.8 ± 0.8 mM-1 s-1 (at 1 T), while Au satellites showed X-ray attenuation in CT. The intravenous injection of nanoparticles enabled clear tumor border visualization in mice. Plasmonic peak in the Fe-Au hybrids had a tail in the near-infrared region (NIR), allowing them to cause hyperthermia under 808 nm laser exposure. Under NIR irradiation Fe-Au particles provided 24.1 °C/W heating and an IC50 value below 32 µg/mL for three different cancer cell lines. Taken together, these results show that laser synthesized Fe-Au core-satellite nanoparticles are excellent theranostic agents with multimodal imaging and photothermal capabilities.Entities:
Keywords: CT; MRI; iron-gold nanoparticles; multimodal imaging; pharmacokinetics; photothermal therapy; pulsed laser ablation in liquids
Year: 2022 PMID: 35631580 PMCID: PMC9144942 DOI: 10.3390/pharmaceutics14050994
Source DB: PubMed Journal: Pharmaceutics ISSN: 1999-4923 Impact factor: 6.525
Figure 1Schematic representation of two-step PLAL synthesis of core-satellite Au-Fe NPs. (a) Laser ablation of gold target with further separation step of 8 nm Au NPs fraction via centrifugation. (b) Laser ablation of iron target in presence of Au NPs with further separation step of magnetic Fe-Au NPs fraction via external magnetic field.
Figure 2Fe-Au NP characterization before and after stabilization with a polymer coating. (a,b) Hydrodynamic size distribution of Fe-Au (a) or Fe-Au@PAA (b) NPs in water and PBS. (c) ζ-potential distributions of Fe-Au nanoparticles before and after the coating with PAA. (d) EDS mapping of Au and Fe abundance in nanoparticles. Scale bar—250 nm. (e) SEM image of Fe-Au@PAA NPs. Scale bar—250 nm. (f) Distribution of Fe-Au@PAA NP physical diameter. (g) Magnetization curves of Fe-Au NPs measured at 300 K. The inset is an enlarged view of the low-field region. (h) UV-Vis spectra of Fe-Au NPs before and after the PAA coating.
Figure 3Photothermal properties of Fe-Au@PAA NPs under NIR-irradiation with 808 nm laser. (a) Temperature changes for aqueous solutions of NPs under irradiation at 1.23 W laser power. (b) Dependence of maximal temperature change on particle concentration. Insert shows thermal images of several particle samples. (c) Dependence of temperature change on laser power. (d) Photothermal stability cycling test with 5 min heating and 5 min cooling steps. © Kinetics of the temperature changes illustrating 1 cycle of 10 min heating and 10 min cooling. (f) The dependence of cooling time on negative natural logarithm of driving force. Solution with 100 µg/mL (c) or 50 µg/mL (d–f) particle concentration was used for the studies.
Figure 4Analysis of the Fe-Au@PAA nanoparticle cytotoxicity using the MTT test. (a) Study of the toxic effect of particles upon exposure to cells BT-474 and SKOV3-1ip. (b–d) Investigation of the photothermic properties of particles. Cells were incubated with Fe-Au@PAA NPs at various concentrations and irradiated for 7 min with an 808 nm laser at 0.76 W power. Cell viability is shown as a percentage normalized to control cells incubated without particles and irradiation. The statistical differences were considered significant when the p value was < 0.05 (*), 0.001 (***), Welch’s t-test.
Figure 5Colony formation assay of EMT6/P and CHO cells treated with Fe-Au@PAA NPs for 8 days with or without 808 nm laser irradiation. Control samples not treated with nanoparticles and irradiation are shown in green frames.
Figure 6Pharmacokinetics of Fe-Au@PAA NPs. Blood circulation (a) and biodistribution (b) of nanoparticles.
Figure 7Application of Fe-Au@PAA NPs as MRI contrast agents. (a) T2-weighted images of NP solutions at 1–1000 mg/L concentrations, distilled water, and air. (b) Inverse of the proton relaxation time T2 as a function of Fe-Au@PAA NP concentration. (c) MR images of EMT6/P tumor bearing mouse after intravenous injection of PBS or Fe-Au@PAA NPs. In the coronal projections (top), a color image of tumor was combined with grey-level image, and scale represents signal intensity. In the axial projections (down), the tumor is bordered by a red dashed line.
Figure 8Application of Fe-Au@PAA NPs as CT contrast agents. (a) CT images of NP solutions at 1–20 g/L concentrations, distilled water, and air. (b) X-ray attenuation coefficient as a function of Fe-Au@PAA NP concentration. (c) CT images of EMT6/P tumor bearing mice before and after intravenous or intratumoral injections of Fe-Au@PAA NPs. The tumor boundary is indicated by a red dashed line in coronal projections (top) or with red arrows at axial projections (down).